Evidence map›Paper›PMID 22828957›Full record

ArticleInternational journal of colorectal disease2012

Metachronous carcinomas in colorectum and its clinicopathological significance.

Alfred King-Yin Lam, Vinod Gopalan, Robert Carmichael, Petra Gertraud Buettner, Melissa Leung, Robert Smith, Cu-Tai Lu, Yik-Hong Ho, Simon Siu

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of colorectal disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alfred King-Yin LamCancer Molecular Pathology, School of Medicine and Griffith Health Institute, Griffith University, Gold Coast, QLD 4222, Australia. a.lam@griffith.edu.au
Vinod Gopalan
Robert Carmichael
Petra Gertraud Buettner
Melissa Leung
Robert Smith
Cu-Tai Lu
Yik-Hong Ho
Simon Siu

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe study was designed to examine the significance of colorectal metachronous carcinoma in a large cohort of patients.

methodsOver a mean follow-up period of 10 years, the clinicopathological features, microsatellite instability (MSI) and clinical follow-up of 56 patients with metachronous colorectal carcinoma were analysed.

resultsThe prevalence of metachronous colorectal carcinoma was 2.1 %. The metachronous colorectal carcinomas appeared between 7 and 246 months (mean = 66 months) after surgical resection of the index colorectal carcinomas. Thirty-six per cent (n = 20) of the metachronous carcinoma occurred more than 5 years after the operation of the index carcinoma. Of the 56 patients, 20 % (n = 11) of the metachronous colorectal carcinomas were mucinous adenocarcinoma. Cancers detected in the secondary operations (metachronous colorectal carcinomas), when compared with the primary index cancers, were smaller, showed higher proportions of mucinous adenocarcinoma and more often located in the proximal colon. Patients with metachronous colorectal cancers had higher prevalence of mucinous adenocarcinoma, loss of staining for MSI markers and better survival rates than other patients with colorectal cancers.

conclusionsPatients with metachronous colorectal carcinomas have characteristic features, and attention to these features is important for better management of this group of cancer.

Indexed as

AdultAgedColorectal NeoplasmsFemaleHumansMaleMicrosatellite InstabilityMiddle AgedNeoplasms, Second PrimarySurvival Analysis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.